DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts ...
Vonvendi is now approved for routine prophylaxis to reduce bleeding frequency in adults with all types of VWD (Type 1, 2, and 3). The Food and Drug Administration (FDA) has expanded the approval of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced interim clinical data from ...
Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ...
Results showed the median ABR for all bleeds was reduced by 54.7%. The Food and Drug Administration (FDA) has approved Vonvendi ® (von Willebrand factor [recombinant]) for routine prophylaxis to ...
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) said that the U.S. Food & Drug Administration approved Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the ...
PARAMUS, N.J., Dec. 5, 2023 /PRNewswire/ -- Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate ®, von Willebrand Factor/Coagulation Factor VIII ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von ...
Von Willebrand disease in dogs is the most common inherited blood disorder our canine friends suffer with, and it also happens in humans and many other species. It’s a bleeding disorder – a failure of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results